Compare 8x8 Inc (EGHT) vs Mesoblast Limited (MESO) Price & Performance

EGHT trades at $2.11, down 1.4% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $27.21 million in 2025 despite revenue of $715.07 million, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights cost-saving wins for clients and AI product growth, with a consensus analyst price target of $19.77 suggesting significant upside potential from current levels.

The outlook hinges on the company's ability to translate top-line growth into sustained profitability. While valuation multiples like a P/S of 0.42 appear attractive, a high P/E of 72 and substantial long-term debt of $338.37 million present risks. The primary opportunity is execution on its financial model to achieve positive net income, as projected for 2026.

MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.

While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.